Sandbox leucocytosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 465: | Line 465: | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Leukoedema | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 472: | Line 473: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Fordyce granules | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 486: | Line 488: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Pyogenic granuloma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 493: | Line 496: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Peripheral ossifying fibroma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 500: | Line 504: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Granular cell tumor | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 507: | Line 512: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Peripheral giant cell granuloma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 514: | Line 520: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Oral hemangioma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 521: | Line 528: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: | | rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | * Benign peripheral nerve sheath tumor | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | |||
* Traumatic neuroma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 529: | Line 538: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Neurofibroma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 536: | Line 546: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Schwannoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 543: | Line 554: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" rowspan="2" | | ||
* Palisaded encapsulated neuroma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 556: | Line 568: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Neodymium-doped yttrium alluminium garnet | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 563: | Line 576: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| rowspan="11" style="background: #DCDCDC; padding: 5px; text-align: | | rowspan="11" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
| rowspan="6" style="background: #DCDCDC; padding: 5px; text-align: | * Pigmented lesions | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | rowspan="6" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Diffuse | |||
| style="background: #DCDCDC; padding: 5px; text-align: left;"| | |||
* Peutz-jeghers syndrome | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 572: | Line 588: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;"| | ||
* Addison's disease | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 579: | Line 596: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;"| | ||
* Heavy metal | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 586: | Line 604: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;"| | ||
* Drug induced | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 593: | Line 612: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;"| | ||
* Post inflammatory | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 600: | Line 620: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;"| | ||
* Smoker's melanosis | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 607: | Line 628: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: | | rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
| style="background: #DCDCDC; padding: 5px; text-align: | * Focal | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;"| | |||
* Ephelides | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 615: | Line 638: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;"| | ||
* Labial melanocytic macules | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 622: | Line 646: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;"| | ||
* Amalgam tattoo | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 629: | Line 654: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;"| | ||
* Oral melanoacanthoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 636: | Line 662: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;"| | ||
* Oral melanocytic nevi | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 650: | Line 677: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Leukoplakia | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 657: | Line 685: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Oral proliferative verrucous leukoplakia | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 664: | Line 693: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Erythroplakia | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 671: | Line 701: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Oral submucus fibrosis | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 678: | Line 709: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Oral lichen planus and lichenoid lesions | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 685: | Line 717: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Oral discoid lupus erythmatosus | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 692: | Line 725: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Oral chronic graft vs host disease | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 699: | Line 733: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Actinic chelitis | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 20:28, 23 January 2019
Disease | Presentation | Risk Factors | Diagnosis | Affected Organ Systems | Important features | Picture |
---|---|---|---|---|---|---|
Diseases predominantly affecting the oral cavity | ||||||
Oral Candidiasis |
|
|
|
Localized candidiasis
Invasive candidasis |
|
|
Herpes simplex oral lesions |
|
|
|
|
||
Aphthous ulcers |
|
|
|
|
|
|
Squamous cell carcinoma |
|
|
||||
Leukoplakia |
|
|
|
|
||
Melanoma |
|
|
|
|
||
Fordyce spots |
|
|
|
|
||
Burning mouth syndrome |
|
|
||||
Torus palatinus |
|
|||||
Diseases involving oral cavity and other organ systems | ||||||
Behcet's disease |
|
|
|
|||
Crohn's disease |
|
|
|
|||
Agranulocytosis |
|
|
||||
Syphilis |
|
|
|
|||
Coxsackie virus |
|
|
||||
Chicken pox |
|
|
|
|
||
Measles |
|
|
|
|
Normal variant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
---|---|---|---|---|---|---|---|
|
|||||||
|
|||||||
Benign Oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|
||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|
|
|||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|
||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
Pre-malignant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
Malignant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
|
Squamous cell carcinoma | ||||||
Basal cell carcinoma | |||||||
Verrucous crcinoma | |||||||
Spindle cell carcinoma | |||||||
Adenoid squamous cell carcinoma | |||||||
Lymphoepithelioma and transitional cell carcinoma | |||||||
Malignant melanoma | |||||||
|
Malignant schwannoma | ||||||
|
Leiomyosarcoma | ||||||
Rhabdomyosarcoma | |||||||
|
Malignant lymphoma | ||||||
Non Hodgkin lymphoma | |||||||
Hodgkin lymphoma | |||||||
Burkitt's lymphoma | |||||||
Reticular cell sarcoma | |||||||
Plasma cell tumor | Multiple myeloma | ||||||
Plasmacytoma | |||||||
|
Fibrosarcoma | ||||||
Liposarcoma | |||||||
|
Granular cell myoblastoma | ||||||
Congenital epulis | |||||||
Alveolar soft part sarcoma | |||||||
Melanocytic neuroectodermal tumor of infancy | |||||||
Kaposi sarcoma | |||||||
Ewing's sarcoma | |||||||
Infections | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
Herpes simplex virus | |||||||
Varicella zoster virus | |||||||
Coxsackie virus | |||||||
HIV infection | |||||||
Syphilis | |||||||
Other infections | |||||||
Autoimmune Conditions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
Oral erosive lichen planus | |||||||
Systemic lupus erythamtosus | |||||||
Mucus membrane pemphigoid | |||||||
Bullous pemphigoid | |||||||
Pemphigus vulgaris | |||||||
Paraneoplastic pemphigus | |||||||
Epidermolysis bullosa acquisita | |||||||
Miscellaneous | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
Burning mouth syndrome | |||||||
Contact stomatitis | |||||||
Cheilitis | |||||||
Mucoceles | |||||||
Torus | |||||||
Dental erosions/Gingival overgrowth | |||||||
Telangiectasias | |||||||
Tongue lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
Atrophic glossitis | |||||||
Fissured tongue | |||||||
Black tongue | |||||||
Black hairy tongue | |||||||
Pigmented fungiform papillae of the tongue | |||||||
Geographic tongue | |||||||
Median rhomboid glossitis |
Type of cancer | Subtype | Epidemiology | Localization | Clinical features | Diagnostic procedures |
---|---|---|---|---|---|
Squamous cell carcinoma
|
Verrucous carcinoma |
|
|
|
Biopsy shows:
Thickened club-shaped papillae and blunt stromal invaginations of well-differentiated squamous epithelium with marked keratinization |
Lymphoepithelial carcinoma | 0.8-2% of all oral or oropharyngeal cancers |
|
|
Biopsy chows:
| |
Epithelial precursor lesions | --- | --- | Seen in the entire digestive tract |
|
Biopsy shows:
|
Proliferative verrucous leukoplakia and precancerous conditions | --- |
|
|
An aggressive form of oral leukoplakia with considerable morbidity and
strong predilection to malignant transformation |
Biopsy shows:
|
Papillomas | Squamous cell papilloma and |
|
Any oral site may be affected mostly:
|
Soft, pedunculated lesions formed by a cluster of finger-like fronds or a sessile, dome-shaped lesion with a nodular, papillary or verrucous surface | Biopsy shows:
|
Condyloma acuminatum | 2nd and 5th decade with a peak in teenagers and young adults |
|
Biopsy shows:
Several sessile, cauliflower-like swellings forming a cluster | ||
Focal epithelial hyperplasia | Disease of children, adolescents and young adults |
|
|
Biopsy shows:
| |
Granular cell tumor | --- |
|
|
|
Biopsy shows:
|
Keratoacanthoma | --- |
whites
men as in women |
|
|
Biopsy shows:
|
Papillary hyperplasia | --- | Affects all age groups | Palate | Asymptomatic nodular or papillary mucosal lesion | Biopsy shows:
|
Median rhomboid glossitis | --- | --- | Dorsum of the tongue at the junction of the anterior two thirds
and posterior third |
Forms a patch of papillary atrophy in the region of the
embryological foramen caecum |
Biopsy shows:
|
Salivary gland tumors | Acinic cell carcinoma |
|
Tumors usually
form non-descript swellings |
Biopsy shows:
| |
Mucoepidermoid carcinoma |
|
|
|
Low power microscopy shows low-grade tumor with both cystic and solid areas and an inflamed, fibrous stroma | |
Adenoid cystic carcinoma |
|
|
Predominantly solid variant shows peri- and intraneural invasion | ||
Epithelial-myoepithelial
carcinoma |
--- | --- | --- | --- | |
Clear cell carcinoma,
NOS |
--- | --- | --- | ||
Basal cell | Rare in minor glands | Asymptomatic, smooth or lobulated sub-mucosal masses | Microscopically similar to basal
cell adenocarcinomas of the major gland | ||
Cystadenocarcinoma | 32% developed in the minor glands |
|
Slow growing and painless but
some palatal tumors may erode the underlying bone causing sinonasal complex |
--- | |
Salivary duct carcinoma |
|
|
Tumors formed painless swellings but many in the palate can be painful and ulcerated or fungated with metastases to regional lymph nodes | The range of
microscopical appearances is similar to that seen in the major glands | |
Salivary gland adenomas | Pleomorphic adenoma | 40-70% of minor gland tumors |
|
Painless, slow growing, submucosal masses, but when | Biopsy shows cellular, and hyaline or plasmacytoid cell |
Myoepithelioma | 42% of minor gland tumors |
|
--- | --- | |
Basal cell adenoma | 20% of minor gland tumors | --- | They are histologically
similar to those in major glands. | ||
Cystadenoma | 7% of benign minor gland tumors | --- | --- | ||
Kaposi sarcoma | --- |
|
|
Biopsy of all 4 types show:
| |
Lymphangioma | --- |
|
Tongue |
|
Biopsy shows:
|
Ectomesenchymal chondromyxoid
tumour of the anterior tongue |
--- |
|
--- | Asymptomatic, slow growing solitary nodule in the anterior dorsal tongue | Biopsy shows:
|
Focal oral mucinosis (FOM) | --- |
|
Asymptomatic fibrous or cystic-like lesion | Histopathology is characterized by:
| |
Congenital granular cell epuli | --- |
|
Solitary, somewhat pedunculated fibroma-like lesion attached to the alveolar
ridge near the midline |
||
Hematolymphoid tumors | Non-Hodgkin lymphoma | Second most common cancer of the oral cavity |
|
NHL of the lip presents with:
|
Biopsy shows:
|
Langerhans cell histiocytosis | --- |
and |
Common oral symptoms
include:
|
Biopsy shows ovoid Langerhans cells
with deeply grooved nuclei, thin nuclear membranes and abundant eosinophilic cytoplasm | |
Hodgkin lymphoma | --- |
|
Most patients present with localized disease (stage I/II), with
|
--- | |
Extramedullary myeloid
sarcoma |
--- | Isolated tumor-forming intraoral mass | Biopsy shows an Indian-file pattern of infiltration | ||
Follicular dendritic cell
sarcoma / tumour |
|
|
The patients usually
present with a painless mass |
Biopsy usually exhibits
borders and comprises:
| |
Mucosal malignant melanoma | --- |
|
80% arise:
Others:
|
|
|